Isomorphic Labs, the AI drug design company founded by DeepMind CEO Demis Hassabis, announced on Monday it has raised $2.1 billion in Series B funding. The round is one of the largest private financings ever in AI-driven drug discovery, bringing the company's total capital base to approximately $2.6 billion.

Thrive Capital, the venture firm led by Joshua Kushner, led the round. Existing backers Alphabet and GV (Google Ventures) participated alongside new investors MGX, Temasek, CapitalG, and notably the UK Sovereign AI Fund, the British government's vehicle for backing domestic AI champions.

The Pitch: AI Can Design Better Drugs, Faster

Isomorphic Labs is built on a simple but audacious thesis: the same AI breakthroughs that powered AlphaFold (Hassabis's Nobel Prize-winning protein structure prediction system) can be turned into a repeatable engine for designing new medicines. The company's internal platform, called IsoDDE (Isomorphic Drug Design Engine), works across multiple therapeutic areas and drug modalities.

"Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential," Hassabis said in the announcement. The company's stated mission remains characteristically bold: "to solve all disease."

Max Jaderberg, President of Isomorphic Labs, pointed to the company's internal drug pipeline as validation: "Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach."

The Investor Coalition Tells a Story

The investor mix is worth parsing. Thrive Capital, which also led major rounds for OpenAI, is now betting big on AI's application layer in healthcare. Temasek brings Singapore's sovereign wealth into the deal. MGX adds Abu Dhabi capital. And the UK Sovereign AI Fund's participation signals that the British government views AI drug discovery as a strategic national asset, not just a commercial play.

Ruth Porat, Alphabet's President and Chief Investment Officer, framed the investment in characteristically measured terms: "The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform."

Where the Money Goes

The $2.1 billion will fund three priorities: continued development and deployment of IsoDDE, accelerating the company's therapeutic pipeline toward clinical trials, and global hiring across AI, engineering, drug design, and clinical talent. The company operates sites in London and has been expanding its headcount aggressively.

Isomorphic Labs describes its approach as "reimagining drug discovery as an integrated scientific and engineering discipline with proprietary AI and data at the core." In practice, this means using generative AI to not just predict protein structures (the AlphaFold breakthrough), but to design novel molecules, predict their behavior in clinical settings, and iterate at speeds that make traditional pharmaceutical R&D cycles look glacial.

The Bigger Picture

This round lands at a pivotal moment for AI in healthcare. The sector has attracted enormous venture capital over the past two years, but most AI drug discovery startups are still in preclinical stages. Isomorphic's ability to raise $2.1 billion, with sovereign wealth funds and the UK government in the cap table, suggests that at least some investors believe the technology has crossed the threshold from promising to proven.

The competitive landscape is intense. Recursion Pharmaceuticals, Insilico Medicine, and several other AI-native drug companies are racing toward the same goal. But none have Hassabis's combination of a Nobel Prize, the DeepMind infrastructure, and Alphabet as a parent company with essentially unlimited compute resources.

The real test comes when Isomorphic's drug candidates enter human trials. Designing molecules with AI is one thing. Getting them through Phase I, II, and III clinical trials is where the pharmaceutical graveyard fills up. The $2.1 billion buys time and talent, but biology doesn't care how impressive your funding round was.

Still, if any team has a shot at proving AI can fundamentally accelerate drug discovery, this is probably the one. And $2.1 billion says the smart money agrees.

First reported by Reuters. Company details via PR Newswire.